Cytosorbents Reports Widened Q1 Loss, Going Concern Warning, and Material Internal Control Weaknesses

summarizeSummary

Cytosorbents reported a significantly widened Q1 net loss, issued a going concern warning, and disclosed persistent material weaknesses in internal controls, despite some improvements in cash burn and operating expenses.

check_boxKey Events

• Going Concern Warning Issued

  The company's cash and expected future cash used in operations raise substantial doubt about its ability to continue as a going concern within the next twelve months.

• Net Loss Widens Significantly

  Q1 2026 net loss widened to $5.1 million, compared to a $1.5 million net loss in Q1 2025.

• Low Cash Position

  Unrestricted cash and cash equivalents stood at $4.8 million as of March 31, 2026, with total cash (including restricted) at $6.3 million.

• Material Weaknesses in Internal Controls

  The company disclosed continuing material weaknesses in accounting for stock-based compensation and newly identified weaknesses in financial statement consolidation and reporting.

auto_awesomeAnalysis

Cytosorbents Corp's Q1 2026 report highlights severe financial distress, including a going concern warning and a significantly widened net loss of $5.1 million, up from $1.5 million in Q1 2025. The company's unrestricted cash stands at a low $4.8 million, raising substantial doubt about its ability to fund operations for the next twelve months. Further compounding these issues are ongoing material weaknesses in internal controls over financial reporting, continuing from 2024 and newly identified in 2025. Delays in FDA approval for DrugSorb-ATR also impact access to a crucial $2.5 million debt tranche, pushing potential funding beyond 2026. While the company has reduced operating expenses and improved its cash burn from operations, these efforts are overshadowed by the precarious financial position and governance concerns. This filing follows a concurrent 8-K that summarized these results.